AACR New Horizons in Cancer Research
Assessment of dianhydrogalactitol (VAL-083) in the treatment of relapsed or refractory non-small cell lung cancer (NSCLC)
European Association for NeuroOncology Annual Meeting
Dianhydrogalactitol (VAL-083) causes irreparable DNA double-strand breaks, S/G2 phase cell-cycle arrest and tumor cell death in an MGMT independent manner offering a unique treatment paradigm for GBM
11th Biennial Ovarian Cancer Research Symposium
Activity of dianhydrogalactitol (VAL-083) in ovarian tumor models, sensitive or resistant to cisplatin
American Association of Cancer Research (AACR) Annual Meeting
Molecular Mechanisms of Dianhydrogalactitol (VAL-083) in Cancer Treatment
American Association of Cancer Research (AACR) Annual Meeting
Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioblastoma
American Association of Cancer Research (AACR) Annual Meeting
Enhanced in vitro activity of dianhydrogalactitol (VAL-083) in combination with platinum drugs: impact of p53 and platinum-resistance
Society for Neuro-Oncology Poster
Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioma
AACR New Horizons in Cancer Research Conference: Bringing Cancer Discoveries to Patients
The unique mechanism of action of dianhydrogalactitol (VAL-083) may provide a new treatment option for chemo-resistant cancers
AACR Advances in Pediatric Cancer Research: From Mechanisms and Models to Treatment and Survivorship
Dianhydrogalactitol (VAL-083) Offers Potential Therapeutic Alternatives in the Treatment of Pediatric Brain